Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 26;8(1):e12331.
doi: 10.1002/trc2.12331. eCollection 2022.

Increasing engagement of Hispanics/Latinos in clinical trials on Alzheimer's disease and related dementias

David X Marquez  1 , Adriana Perez  2 , Julene K Johnson  3 , Michelle Jaldin  1 , Juan Pinto  1 , Sahru Keiser  3 , Thi Tran  3 , Paula Martinez  3 , Javier Guerrero  3 , Elena Portacolone  3   4
Affiliations

Increasing engagement of Hispanics/Latinos in clinical trials on Alzheimer's disease and related dementias

David X Marquez et al. Alzheimers Dement (N Y). .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Alzheimers Dement (N Y). 2022 Sep 26;8(1):e12354. doi: 10.1002/trc2.12354. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 36185994 Free PMC article.

Abstract

Introduction: Despite evidence that Hispanic/Latino populations are 1.5 times more likely than non-Latino Whites to develop Alzheimer's disease and related dementias (ADRD), Latinos are underrepresented in clinical trials testing treatments for ADRD. Data are needed on facilitators of ADRD clinical trial participation in Latinos. We leveraged in-depth qualitative methods to elucidate barriers and facilitators to participating in ADRD clinical trials in a large and diverse sample of Latinos; and to provide timely and actionable strategies to accelerate representation of Latinos in clinical trials on ADRD.

Methods: Data were collected in California between January 2019 and June 2020 from 25 focus groups (FGs): eight with Latino adults ages 18 to 49 (n = 54), nine with Latino adults ages 50+ (n = 75), and eight with caregivers of Latino older adults with ADRD (n = 52). Twelve community-based organization administrators were also interviewed. Transcripts of FGs and interviews were entered into Atlas.ti software. Three independent team members analyzed the transcripts with inductive/deductive qualitative content analysis. We triangulated data from stakeholder groups across sites, we used collaborative coding, and used the Consolidated Criteria for Reporting Qualitative Research.

Results: An overarching theme was a tension between wanting to learn more about ADRD and to participate in ADRD research but having limited awareness and opportunity. Five themes were identified: (1) remaining in limbo, (2) wanting information about ADRD, (3) wanting information on research about ADRD, (4) clearing researchers through trusted local organizations, and (5) practicing altruism through engagement in research opportunities.

Discussion: To increase representation of Latino communities in clinical trials on ADRD, bilingual information and education on ADRD and clinical trials needs to be better disseminated. Also, working with trusted local, regional, and national organizations can increase participation. Importantly, Latino participation can increase when research teams demonstrate altruistic actions and inform participants of public health reasons requiring their involvement.

Highlights: Participation in clinical trials on Alzheimer's disease and related dementias (ADRD) is limited among Latinos/Hispanics.Knowing the high prevalence of ADRD in Latinos increases willingness to participate.Observing altruism from researchers increases willingness to participate.Invitations from multiple organizations increases willingness to participate.Researchers should include public health reasons requiring Latinos' involvement.

Keywords: Alzheimer's disease and related dementias; Hispanic; Latino; aged; clinical trials; focus groups.

PubMed Disclaimer

Conflict of interest statement

All the authors declared that they do not have conflict of interest.

Figures

FIGURE 1
FIGURE 1
The Ford et al. conceptual framework
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Manly JJ, Gilmore‐Bykovskyi A, Deters KD. Inclusion of underrepresented groups in preclinical Alzheimer disease trials‐opportunities abound. JAMA Netw Open. 2021;4(7):e2114606. - PubMed
    1. US Census. Hispanic or Latino table. census.gov: U.S. Census Bureau; 2020 2020.
    1. Canevelli M, Bruno G, Grande G, et al. Race reporting and disparities in clinical trials on Alzheimer's disease: a systematic review. Neurosci Biobehav Rev. 2019;101:122‐128. - PubMed
    1. National Institutes of Health . NIH RCDC Inclusion Statistics Report. National Institutes of Health, 2022.
    1. Manly JJ, Glymour MM. What the aducanumab approval reveals about Alzheimer disease research. JAMA Neurol. 2021;78(11):1305‐1306. - PubMed